ArticleJACC. Case reports2026
Carcinoid Heart Disease: 17-Year Follow-Up of Right Heart Double Bioprosthetic Valve Replacement.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBioprosthetic valve replacement in patients with carcinoid heart disease (CHD) is effective, although valve degeneration from persistent serotonin exposure is a concern, and long-term survival beyond 1 decade is rare. CASE SUMMARY: We report a 46-year-old woman with CHD who underwent tricuspid and pulmonary bioprosthetic valve replacement in 2007, followed by hepatic tumor resection. Over a 17-year follow-up, she required interventions for tumor recurrence and atrial flutter. Notably, serial echocardiography demonstrated sustained bioprosthetic valve function without structural deterioration. She remains at NYHA functional class I-II status. DISCUSSION: In this case, the patient exceeded the typical median survival (2-3 years) for CHD, suggesting that aggressive multimodal management and serotonin control can prevent bioprosthetic degeneration and ensure long-term survival. TAKE-HOME MESSAGE: With multidisciplinary oncologic and surgical care, bioprosthetic valves in CHD patients can demonstrate exceptional durability (17 years), offering prolonged survival and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.